​​​​​​​​​​​​​​

Hæder til to yngre børnekræftforskere fra Rigshospitalet

​Idrætsforsker Martin Kaj Fridh og læge Ulrik Stoltze fra Afdeling for Børn og Unge fra har begge vundet en af SIOP’s Young Invevstigator Awards for deres forskning inden for børnekræftområdet.

Martin Kaj Fridh, der er idrætsfysiolog, ph.d. og post.doc ved BonkoLab (Børneonkologisk Laboratorium) i Afdeling for Børn og Unge, får prisen for sin forskning om det træningsprogram, som han sammen med andre forskere og klinikere på Rigshospitalet har udviklet og evalueret. Træningsprogrammet er en del af RESPECT-projektet, hvor børn og unge med jævne mellemrum også får besøg af en af deres skolekammerater på hospitalet – en såkaldt ambassadør.

Ulrik Stoltze, der er afdelingslæge, ph.d. og forsker i Afdeling for Børn og Unge, får prisen for sin forskning, hvor han har kunnet vise, at størstedelen af danske piger med kræft i nyren, har en underliggende (Epi-)gentisk tilstand, der har forårsaget kræften. 

Prisen ’Young Investigator Award’ uddeles hvert år af det internationale selskab for børnekræft SIOP (International Society of Peadiatric Oncology).

Alle abstracts fra forskere under 40 inden for området indstilles til at modtage prisen og de højeste rangerede abstracts inden for hver kategori tildeles prisen. Prisen uddeles for at give yngre forskere muligheden for at præsentere deres forskning på SIOP-konferencen, og dermed både øve sig i at præsentere og få mulighed for at fortælle om deres forskningsprojekter internationalt. 

Priserne blev uddelet på SIOP’s konference i Barcelona den 28. sept. – 1. oktober 2022. 

- Jeg er enormt beæret over at modtage prisen! Det betyder, at rehabilitering for børn og unge med kræft kommer mere i fokus internationalt, udtaler Martin Kaj Fridh, der er stolt af at modtage prisen, men understreger, at hæderen også skal tilgå de kolleger, der har været med til at udarbejde publikationen bag abstractet, dvs. forskere fra både Rigshospitalet, Odense Universitetshospital, og Aarhus Universitetshospital.

- Jeg stolt af og taknemmelig for, at SIOP anerkender vores lille studie, og jeg er taknemmelig for, at patienterne og forældrene, samt Rigshospitalets forskningsfond og Børnecancerfonden​ giver mig muligheden for, dag efter dag, at sidde og kigge børnenes data igennem. Forskning er ofte ganske frustrerende og usikkert - og skal nok være det til en vis grad. Så det er helt rart at få en lille chance for lige at stoppe op og nyde det lidt, udtaler Ulrik Stoltze.



​​​​Foto: ​Ulrik Stoltze og Martin Kaj Fridsh fra Afdeling for Børn og Unge ​.


​​Martin Kaj Fridh abstract på ​engelsk

​Effects of a physical activity program for children and adolescents with cancer from diagnosis to one-year post treatment on cardiorespiratory fitness and physical function.

​Background and​​ Aims

Childhood cancer survivors experience impaired cardiorespiratory fitness and physical function restricting their possibilities to engage in social activities including sport, leisure activities and school. The study objective was to determine the effects of classmate-supported, supervised, in-hospital physical activity program during treatment on primarily cardiorespiratory fitness and secondarily on physical function one-year after ended treatment.

Met​​hods

National non-randomized controlled trial including schoolchildren aged 6–18 years at diagnosis treated with chemo-/radiotherapy. Seventy-five of 120 included children in the intervention group (61% boys, 13.4±3.1 years), and 33 of 58 in control group (58% boys, 13.5±2.5 years) participated in testing post-treatment. Anthropometrics and cancer diagnoses were comparable between groups (p>0.05). The intervention consisted of: (i) supervised in-hospital physical activity from diagnosis and throughout intensive treatment; (ii) 90-minutes general educational session on cancer and therapy in the child’s school class; and (iii) selection of two classmates as ambassadors who took turns to be co-admitted to the hospital and support the child’s physical training during the daytime. The primary outcome was cardiorespiratory fitness (VO2peak, mL/min/kg) (sex, age, diagnosis adjusted). Secondary outcomes were Sit-To-stand, Timed-Up-and-Go, Handgrip strength, and balance test scores.

Trial registration: 11. January 2013. Clinicaltrial.gov NCT01772849 and NCT01772862.

Result​s

All children had ambassadors allocated. In the intervention group, a total of 3364 individual and 726 group sessions were held, with a median of 34 session [4-85]. One-year post-treatment termination, VO2peak was higher in the intervention group (37.4±5.7 mL/kg/min) than the control group (32.3±9.7 mL/kg/min) (p=0.015). The intervention group had a better Sit-To-stand (29.7±5.4 vs 23.2±5.4 reps, p<0.001), Timed-Up-and-Go (3.4±0.4 vs 5.4±0.6 seconds, p<0.001), and Handgrip strength (26.9±12.0 vs 21.6±10.4 kg, p=0.014). Balance scores were comparable between groups.

Conc​​lusions

Peer-supported, supervised, in-hospital, physical activity during treatment can cardiorespiratory fitness and physical function after ended treatment.

Hele publikationen kan læses på Pubmed. 


​Ulrik Stoltzes Abstract på engelsk

​Comprehensive germline genomics of patients with wilms tumor reveals a high level of predisposition in females

​Background and Aims

Wilms tumour (WT) has excellent event-free and overall survival rates. However, those with advanced disease have more variation in adherence to the treatment protocol. We examined the extent of variation and its possible effects on survival

Methods

Retrospective analysis of all children with unilateral WT treated with pre-operative chemotherapy in the SIOPWT2001 (2002-11) and IMPORT (2012-18) studies in the UK and Ireland. Pre- and post-operative treatments (including radiotherapy) were classified as: per protocol (PP); deviation (PDEV) - variation for specified clinical reasons; violation (PVIOL) - not treated within protocol-defined parameters. Survival analysis was conducted by Kaplan-Meier, to calculate 2 and 5 year OS and EFS.

Results

1130 children with WT were registered by 20 centres. 1044 (92%) had unilateral WT treated with pre-operative chemotherapy. All had centrally reviewed pathology. Case Report Forms allowing categorisation of the whole treatment pathway were available for 752 patients. Survival rates for both studies were identical, with 5-year OS 92% and 5-year EFS 86%. For patients with localised disease (Stage I-III) 5-year EFS was 88% for PP (n=402) and PDEV (n=123) and 84% for PVIOL (n=72), corresponding 5-year OS was 96%, 95% and 93%, respectively. For patients with metastatic disease (Stage IV), 5-year EFS was 80% for PP (n=45) and PDEV (n=50) and 83% for PVIOL (n=54), corresponding 5-year OS was 89%, 78% and 90%, respectively. None of these differences were statistically significant. In SIOPWT2001 33% of PVIOL patients could be categorised as over-treated and 56% as under-treated. In IMPORT, 47% were over-treated and 45% were under-treated.

Conclusions

Variation in adherence to protocol recommendations is more common in Stage IV disease. Whilst variation does not affect 5-year EFS or OS, it comprises both over- and under-treatment, which may affect risks of late effects.

Se beskrivelsen af forskningen på SIOP's konferencesite

Redaktør